Nanoparticle Targeting CD44-Positive Cancer Cells for Site-Specific Drug Delivery in Prostate Cancer Therapy

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Oncology

Background:

• Prostate cancer presents significant therapeutic challenges, particularly for recurrent and metastatic disease.
• CD44, a cell surface glycoprotein, plays a crucial role in cancer cell proliferation and migration.
• Targeting CD44-positive cancer cells offers a promising therapeutic strategy.

Purpose of the Study:

• To develop a biocompatible, hyaluronic acid-based nanoparticle system for targeted delivery of epigallocatechin-3-gallate (EGCG) to CD44-positive prostate cancer cells.
• To evaluate the efficacy of EGCG-loaded nanoparticles in inhibiting prostate cancer cell growth and tumor progression both in vitro and in vivo.

Main Methods:

• Fabrication of negatively charged, hyaluronic acid-based nanoparticles encapsulating EGCG.
• In vitro assessment of nanoparticle internalization into CD44-positive cancer cells and induction of cell cycle arrest.
• In vivo studies to evaluate nanoparticle targeting specificity, tumor growth inhibition, and reduction of tumor-associated inflammation.

Main Results:

• Hyaluronic acid nanoparticles efficiently encapsulated EGCG and were internalized by cancer cells through CD44 receptor recognition.
• Nanoparticle treatment induced G2/M phase cell cycle arrest and inhibited prostate cancer cell proliferation in vitro.
• In vivo studies demonstrated specific binding to CD44 receptors, increased cancer cell apoptosis, significant tumor growth reduction, and decreased inflammation.

Conclusions:

• Hyaluronic acid-based nanoparticles serve as an effective drug delivery system for EGCG in targeting CD44-positive prostate cancer.
• This targeted nanotherapeutic approach shows potential for inhibiting prostate cancer progression and associated inflammation.